Success Metrics

Completion Rate

0%(0/2)

Active Trials

0(0%)

Terminated

2(100%)

Phase Distribution

Ph phase_1

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution2 total trials

Phase 1Safety & dosage

2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Terminated(2)

Detailed Status

Terminated2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

terminated2100%

Recent Activity

0 active trials

Showing 2 of 2

terminatedphase_1

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

NCT03739138

terminatedphase_1

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

NCT03065023

Clinical Trials (2)

Showing 2 of 2 trials

NCT03739138Phase 1

Intratumoral/Intralesional Administration of MK-4621/JetPEI™ With or Without Pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002)

Terminated

NCT03065023Phase 1

Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001)

Terminated

All 2 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 2